FAIR VALUE DISCLOSURES (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended									3 Months Ended	12 Months Ended
		Dec. 31, 2017	Feb. 28, 2017	Apr. 30, 2016	Jan. 31, 2016	Aug. 31, 2015	Jul. 31, 2015	May 31, 2015	Mar. 31, 2015	Dec. 26, 2013	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate												15.00%
Payments to Acquire Intangible Assets			$ 30,600									$ 97,624	$ 144,494	$ 30,500
Long-term Debt, Gross		$ 143,750									$ 143,750	143,750	143,750
Long-term Debt, Total		128,208									120,643	128,208	120,643
Finite-Lived Intangible Assets, Gross		284,716									203,992	284,716	203,992
Inventory, Finished Goods, Gross	[1]	13,901									10,812	13,901	10,812
Accrued Royalties Related To Asset Purchase												0	3,882	0
Impairment of Intangible Assets, Finite-lived												903	6,685	0
Assets Held-for-sale, Not Part of Disposal Group, Current											900		900
Asset Purchase Contingent Consideration Non Probable		3,000										3,000
Goodwill [Member]
Fair Value Inputs, Assets, Quantitative Information
Goodwill, Impairment Loss												$ 0	0	$ 0
Cranford Pharmaceuticals [Member] | Non Compete Agreement [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate				10.00%
Finite-Lived Intangible Assets, Gross				$ 600
Finite-Lived Intangible Asset, Useful Life				7 years
Inderal XL [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			10.00%
Payments to Acquire Intangible Assets			$ 20,200
Finite-Lived Intangible Assets, Gross			$ 15,100
Finite-Lived Intangible Asset, Useful Life			10 years									10 years
Acquisition Costs Capitalized			$ 40
Inventory, Finished Goods, Gross			$ 5,000
InnoPran XL [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			10.00%
Payments to Acquire Intangible Assets			$ 30,600
Finite-Lived Intangible Assets, Gross			$ 19,000
Finite-Lived Intangible Asset, Useful Life			10 years
Acquisition Costs Capitalized			$ 100
Inventory, Finished Goods, Gross			11,600
InnoPran XL [Member] | Cash [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets			600
InnoPran XL [Member] | Line of Credit [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets			$ 30,000
Merck Sharp Dohme B.V. [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate					10.00%
Finite-Lived Intangible Assets, Gross					$ 75,000
Finite-Lived Intangible Asset, Useful Life					10 years
Acquisition Costs Capitalized					$ 300
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information
Theoretical Interest Rate For Debt Without Embedded Conversion Option															9.00%
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information
Notes Payable, Fair Value Disclosure		164,300										$ 164,300
Convertible Senior Notes [Member]
Fair Value Inputs, Assets, Quantitative Information
Long-term Debt, Gross															$ 143,800
Exercise Price Of Bond Hedge															$ 69.48
Underlying Shares Of Common Stock Bond Hedge														2,068,792	2,068,792
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 96.21	$ 96.21
Net Adjustments To Additional Paid In Capital Bond Hedge Acquired Warrant Issued Net															$ 15,600
New Drug Applications [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets				$ 64,200
New Drug Applications [Member] | Cranford Pharmaceuticals [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate				12.00%
Payments to Acquire Intangible Assets				$ 60,000
Finite-Lived Intangible Assets, Gross				$ 52,400
Finite-Lived Intangible Asset, Useful Life				10 years
Acquisition Costs Capitalized				$ 300
Inventory, Finished Goods, Gross				10,900
Funds Held In Escrow In Relation To Asset Purchase				5,000
Accrued Royalties Related To Asset Purchase				$ 3,900
Acquired ANDA Intangible Assets [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate							10.00%
Payments to Acquire Intangible Assets							$ 25,000		$ 4,500	$ 12,500
Finite-Lived Intangible Assets, Gross		42,076					$ 25,000		$ 4,500		42,076	$ 42,076	42,076
Finite-Lived Intangible Asset, Useful Life							10 years		10 years	10 years		10 years
Marketing and Distribution Rights [Member]
Fair Value Inputs, Assets, Quantitative Information
Finite-Lived Intangible Assets, Gross		$ 11,042				$ 1,000					11,042	$ 11,042	11,042
Finite-Lived Intangible Asset, Useful Life						7 years						4 years 8 months 12 days
Marketing and Distribution Rights [Member] | H2 - Pharma, LLC [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate					10.00%
Payments to Acquire Intangible Assets					$ 8,800
Finite-Lived Intangible Assets, Gross					10,000
Acquisition Costs Capitalized					42
Accrued Royalties Assumed in Asset Purchase					$ 1,200
Testosterone Gel NDA [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value Inputs, Assets, Quantitative Information
Assets Held-for-sale, Not Part of Disposal Group, Current											$ 900		900
Testosterone Gel NDA [Member] | New Drug Applications [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate											30.00%
Finite-Lived Intangible Assets, Gross											$ 10,900		10,900			$ 10,900
Royalty Rate								5.00%			5.00%
Impairment of Intangible Assets, Finite-lived												$ 900	$ 6,700
Maximum Royalties Potentially Payable								$ 5,000			$ 5,000
AstraZeneca AB and AstraZeneca UK Limited [Member] | New Drug Applications [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate		10.00%
Payments to Acquire Intangible Assets		$ 46,500
Finite-Lived Intangible Assets, Gross		$ 46,700										$ 46,700
Finite-Lived Intangible Asset, Useful Life		10 years
Acquisition Costs Capitalized		$ 200

[1] Includes finished goods acquired in asset purchases (Note 6).